WallStreetZenWallStreetZen

NASDAQ: JSPR
Jasper Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for JSPR

Based on 3 analysts offering 12 month price targets for Jasper Therapeutics Inc.
Min Forecast
$65.00+193.98%
Avg Forecast
$71.67+224.14%
Max Forecast
$80.00+261.83%

Should I buy or sell JSPR stock?

Based on 3 analysts offering ratings for Jasper Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their JSPR stock forecasts and price targets.

JSPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-03
lockedlocked$00.00+00.00%2024-03-28
lockedlocked$00.00+00.00%2024-03-07

1 of 1

Forecast return on equity

Is JSPR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.5%

Forecast return on assets

Is JSPR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

JSPR revenue forecast

What is JSPR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$44.0M
Avg 2 year Forecast
$4.2M
Avg 3 year Forecast
$32.3M

JSPR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JSPR$22.11$71.67+224.14%Buy
RANI$6.69$9.67+44.50%Strong Buy
ATAI$1.97$10.50+432.99%Strong Buy
LXEO$12.14$21.20+74.63%Strong Buy
RVNC$3.66$13.43+266.91%Buy

Jasper Therapeutics Stock Forecast FAQ

Is Jasper Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: JSPR) stock is to Buy JSPR stock.

Out of 3 analysts, 0 (0%) are recommending JSPR as a Strong Buy, 3 (100%) are recommending JSPR as a Buy, 0 (0%) are recommending JSPR as a Hold, 0 (0%) are recommending JSPR as a Sell, and 0 (0%) are recommending JSPR as a Strong Sell.

If you're new to stock investing, here's how to buy Jasper Therapeutics stock.

What is JSPR's revenue growth forecast for 2025-2027?

(NASDAQ: JSPR) Jasper Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Jasper Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast JSPR's revenue for 2025 to be $662,811,424, with the lowest JSPR revenue forecast at $662,811,424, and the highest JSPR revenue forecast at $662,811,424. On average, 3 Wall Street analysts forecast JSPR's revenue for 2026 to be $63,569,641, with the lowest JSPR revenue forecast at $19,583,065, and the highest JSPR revenue forecast at $150,638,960.

In 2027, JSPR is forecast to generate $486,307,755 in revenue, with the lowest revenue forecast at $138,738,482 and the highest revenue forecast at $974,634,071.

What is JSPR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: JSPR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is JSPR's Price Target?

According to 3 Wall Street analysts that have issued a 1 year JSPR price target, the average JSPR price target is $71.67, with the highest JSPR stock price forecast at $80.00 and the lowest JSPR stock price forecast at $65.00.

On average, Wall Street analysts predict that Jasper Therapeutics's share price could reach $71.67 by Apr 3, 2025. The average Jasper Therapeutics stock price prediction forecasts a potential upside of 224.14% from the current JSPR share price of $22.11.

What is JSPR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: JSPR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.